INTRODUCTION {#S1}
============

Estrogen receptor-positive (ER^+^) breast cancers represent a significant challenge to modern health care. ERα-dependent transcription in these cancers potentiates cell proliferation and malignancy. Estrogen (E2) binding leads to conformational changes within ERα that promote dimerization, binding to estrogen response elements (EREs), and subsequent cofactor recruitment ([@R10]). Binding of ERα to EREs is promoted by the pioneer factor, Forkhead protein FOXA1 (HNF3α) ([@R7]; [@R19]). ERα also functions along with Cohesin ([@R43]) to facilitate long-range chromosomal interactions between EREs ([@R15]).

The regulation of transcriptional elongation plays an essential role in E2-dependent gene transcription. This is largely regulated by the activity of the Positive Transcription Elongation Factor-b (P-TEFb) complex ([@R38]). P-TEFb promotes elongation in part by relieving negative regulation by phosphorylating negative elongation factor (NELF) and dichloro-1-β-D-ribofuranosylbenzimidazole (DRB)-sensitivity inducing factor (DSIF) complexes. Pausing of RNA polymerase II (RNAPII) by NELF just downstream of the transcriptional start site (TSS) is a critical determinant of ERα-dependent transcription ([@R1]). P-TEFb also phosphorylates Ser2 (p-Ser2) within the heptapeptide repeat of the RNAPII carboxy-terminal domain (CTD). This in turn promotes elongation-associated histone modifications including histone H2B monoubiquitination (H2Bub1) ([@R22]; [@R40]), which is required for E2-dependent transcription ([@R5]; [@R41]). Consistently, E2-dependent transcription was shown to be regulated at a post-RNAPII recruitment step involving increased RNAPII p-Ser2 by P-TEFb ([@R25]).

The Bromodomain-containing Protein 4 (BRD4) binds to acetylated histones at both enhancers and promoters and recruits P-TEFb to support lineage-specific gene transcription ([@R59]; [@R58]). Importantly, inhibition of BRD4 by pan-bromodomain and extraterminal domain (BET) inhibitors such as JQ1 ([@R13]), PFI-1 ([@R39]), and IBET revealed the involvement of BRD4 in various cancers in animal models ([@R17]; [@R31]; [@R36]; [@R57]; [@R61]). Moreover, a BRD4-dependent gene expression signature was reported to be a positive predictor of breast cancer survival ([@R8]) and has been implicated as an inherent susceptibility gene for metastasis in breast cancers ([@R2]).

Recent findings describe a role for enhancer RNA (eRNA) production from ERα-bound enhancers during E2-regulated transcription ([@R16]; [@R28]). eRNAs are noncoding RNAs that promote transcription by an unknown mechanism ([@R24]). Interestingly, cyclin-dependent kinase 9 (CDK9) is required for E2-regulated eRNA synthesis ([@R16]).

In this study, we investigated a role for BRD4 as a transcriptional cofactor of ERα-induced transcription by regulating transcriptional elongation and revealed its recruitment both to gene promoters as well as FOXA1-ERα-bound enhancers in ER^+^ breast cancer cells. Moreover, we demonstrate that distal EREs that produce eRNAs are enriched for BRD4 occupancy and uncover a role for BRD4 in eRNA synthesis.

RESULTS {#S2}
=======

BRD4 Regulates E2-Induced Transcriptional Activity in ER^+^ Cancers {#S3}
-------------------------------------------------------------------

To analyze the importance of BRD4 in ERα-dependent gene regulation, we performed mRNA sequencing (mRNA-seq) analyses in ER^+^ breast cancer cells following E2 stimulation in cells depleted for BRD4 or treated with the BRD4 inhibitor, JQ1 ([Figure S1A](#SD1){ref-type="supplementary-material"}). Heatmap analysis shows a nearly global decrease of E2-stimulated gene expression following BRD4 depletion and inhibition ([Figures 1A](#F1){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}), whereas the effects of BRD4 perturbation in this time frame were less apparent for E2-downregulated genes ([Figure S1D](#SD1){ref-type="supplementary-material"}). The inhibition of E2-induced transcription by BRD4 perturbation was further verified for representative E2-upregulated genes ([Figure S1B](#SD1){ref-type="supplementary-material"}). Strikingly, in addition to the known targets of BRD4 such as cell proliferation-specific and tumor necrosis factor-nuclear factor κB target genes ([@R35]; [@R60]), gene set enrichment analyses (GSEAs) identified multiple E2- and ERα-related pathways as being significantly enriched following BRD4 knockdown or inhibition under vehicle (Veh) as well as E2-treated conditions ([Figures 1B](#F1){ref-type="fig"}, [S1E](#SD1){ref-type="supplementary-material"}, and [S1F](#SD1){ref-type="supplementary-material"}). Similar effects were also seen in the ER^+^ Ishikawa endometrial cancer cell line ([Figure S1G](#SD1){ref-type="supplementary-material"}), whereas BRD4 depletion had little or no effect on transforming growth factor β1 (TGF-β1)-induced gene expression ([Figure S1H](#SD1){ref-type="supplementary-material"}). Together, these findings indicate a specific and central role for BRD4 in regulating E2-induced transcription in ER^+^ cancers.

BRD4 Regulates RNAPII Phosphorylation and H2Bub1 {#S4}
------------------------------------------------

Given the importance of BRD4 in controlling RNAPII elongation ([@R30]; [@R37]), and the established roles for RNAPII p-Ser2 ([@R25]) and H2Bub1 ([@R41]) in E2-induced gene transcription, we examined whether BRD4 depletion or inhibition affects RNAPII p-Ser2 or H2Bub1. Interestingly, both RNAPII p-Ser2 and H2Bub1 substantially increased upon E2 treatment, and depletion or inhibition of BRD4 decreased their levels under basal as well as E2-induced conditions ([Figures 1C](#F1){ref-type="fig"}, [1D](#F1){ref-type="fig"}, and [S1J](#SD1){ref-type="supplementary-material"}). Similar effects were also observed in Ishikawa and H1299 cells upon BRD4 depletion ([Figure S1I](#SD1){ref-type="supplementary-material"}).

BRD4 Regulates ERα-Dependent Cell Proliferation and Uterine Growth {#S5}
------------------------------------------------------------------

In order to investigate the physiological function of BRD4 in controlling ERα activity, we examined cell proliferation after knockdown or inhibition of BRD4 in both MCF7 and Ishikawa cells. Notably, consistent with gene expression results ([Figures 1A](#F1){ref-type="fig"}, [1B](#F1){ref-type="fig"}, and [S1B--S1F](#SD1){ref-type="supplementary-material"}), BRD4 perturbation decreased cell proliferation in a manner similar to the pure anti estrogen ICI182780 both in the presence and absence of E2 ([Figures 2A](#F2){ref-type="fig"}, [S2A, and S2B](#SD1){ref-type="supplementary-material"}).

Decreased uterine weight is a hallmark of diminished estrogen signaling in vivo. Consistent with in vitro experiments, JQ1-injected mice demonstrated a substantial decrease in uterine growth ([Figure 2B](#F2){ref-type="fig"}) and uterine wet weight ([Figure 2C](#F2){ref-type="fig"}), without significant changes in total body weight ([Figure S2C](#SD1){ref-type="supplementary-material"}). Gene expression analyses confirmed decreased expression of E2-dependent genes in uteri from JQ1-injected mice ([Figure 2D](#F2){ref-type="fig"}), confirming a central role for BRD4 in controlling E2-induced proliferation and growth both in vitro and in vivo.

BRD4 Occupancy Is Associated with an Active Epigenetic Context and Transcription {#S6}
--------------------------------------------------------------------------------

To gain mechanistic insight into the function of BRD4 and H2Bub1 in ERα-regulated transcription, we performed genome-wide chromatin immunoprecipitation (ChIP) and sequencing (ChIP-seq) analyses. Consistent with its role in E2-induced gene transcription, genome-wide profiling and single-gene analyses revealed increased BRD4 occupancy slightly downstream of the TSS and continuing into the transcribed region of E2-induced genes ([Figures 3A](#F3){ref-type="fig"}, [3B](#F3){ref-type="fig"}, and [S3A--S3G](#SD1){ref-type="supplementary-material"}). This occupancy is decreased upon JQ1 treatment ([Figure S3B](#SD1){ref-type="supplementary-material"}). Conversely, E2 reduced BRD4 recruitment on E2-repressed genes ([Figures S3D and S3F](#SD1){ref-type="supplementary-material"}). Consistent with a previous study by [@R34], H2Bub1 preferentially occupied gene bodies ([Figures 3C](#F3){ref-type="fig"}, [3D](#F3){ref-type="fig"}, and S3H--S3L). Notably, E2 treatment increased H2Bub1 levels on E2-stimulated genes significantly, and this effect was reduced by JQ1 treatment ([Figures 3C](#F3){ref-type="fig"}, [S3I, and S3K--S3M](#SD1){ref-type="supplementary-material"}). Interestingly, the effect of JQ1 on H2Bub1 occupancy was most pronounced on genes exhibiting de novo RNAPII recruitment, such as *GREB1* and *TFF1*, but less on RNAPII-recruited and -preloaded and -constitutively bound genes like *XBP1* ([Figures S3K and S3N](#SD1){ref-type="supplementary-material"}).

Correlation and aggregate plots confirmed an association of BRD4 and active transcription on E2-induced TSSs ([Figures 3E](#F3){ref-type="fig"}, [3F](#F3){ref-type="fig"}, and [S3O--S3R](#SD1){ref-type="supplementary-material"}). Moreover, BRD4 occupancy positively correlated with histone marks H3K27ac and H3K4me3, which are hallmarks of active transcription, as well as RNAPII, H2Bub1, and DHSs (DNase I-hypersensitivity sites), but not with H3K27me3 ([Figures 3E](#F3){ref-type="fig"} and [S3O](#SD1){ref-type="supplementary-material"}). Similarly, H2Bub1 also correlated with transcription, H3K4me3, BRD4, H3K27ac, and RNAPII ([Figures 3E](#F3){ref-type="fig"} and [S3O](#SD1){ref-type="supplementary-material"}). Grouping of TSSs according to the level of nascent RNA expressed (high, medium, low, and null) and aggregate plot and heatmap analyses revealed a clear association of BRD4, H3K27ac, H3K4me3, RNAPII, and H2Bub1 occupancy as well as DHSs and gene transcription ([Figures 3F](#F3){ref-type="fig"} and [S3P--S3R](#SD1){ref-type="supplementary-material"}).

BRD4 Functions Downstream of ERα, H3K27ac, and Cohesin {#S7}
------------------------------------------------------

Because BRD4 inhibition prevents E2-dependent gene induction without appreciably affecting ERα protein levels ([Figures 1D](#F1){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}), we also examined the effects of JQ1 treatment on the recruitment of ERα and the Cohesin subunit RAD21. Single-gene analyses of ERα binding suggested that ERα binding is not affected at specific EREs after BRD4 inhibition ([Figures 4A](#F4){ref-type="fig"} and [S4B](#SD1){ref-type="supplementary-material"}). Consistent with a recent report describing an effect of BRD4 inhibition on androgen receptor (AR) recruitment ([@R4]), genome-wide analyses confirmed that JQ1 treatment decreases ERα binding at most EREs ([Figures 4B](#F4){ref-type="fig"}, [S4D, and S4E](#SD1){ref-type="supplementary-material"}). However, these effects are only partial, and substantial levels of ERα are still bound to EREs after JQ1 treatment ([Figure S4F](#SD1){ref-type="supplementary-material"}). Consistent with the recent studies that BRD4 does not promote chromosomal looping between enhancers and promoters ([@R30]), RAD21 binding to three different EREs known to serve as hubs for ERα-dependent looping ([@R15]) was unaffected by JQ1 treatment ([Figure S4C](#SD1){ref-type="supplementary-material"}). Interestingly, whereas BRD4 binding correlated with H3K27ac ([Figure 3E](#F3){ref-type="fig"}) ([@R58]), BRD4 inhibition did not influence the E2-induced H3K27ac on individual E2-regulated enhancers and promoters ([Figures 4C](#F4){ref-type="fig"} and [S4H](#SD1){ref-type="supplementary-material"}). These results suggest that BRD4 is recruited to E2-regulated genes subsequent to ERα binding, histone acetylation, and Cohesin recruitment.

BRD4 Occupies Enhancers and Regulates eRNA Synthesis by Affecting RNAPII Recruitment and Elongation {#S8}
---------------------------------------------------------------------------------------------------

BRD4 was recently shown to occupy and regulate enhancer function ([@R30]; [@R58]). Thus, we examined BRD4 occupancy at distal EREs and observed that BRD4 is recruited to distal EREs in an E2-dependent manner and correlated with H3K27ac, ERα, FOXA1, RNAPII, and DHS ([Figures 4D](#F4){ref-type="fig"}, [4E](#F4){ref-type="fig"}, [4H](#F4){ref-type="fig"}, [S4G](#SD1){ref-type="supplementary-material"}, and [S4I--S4L](#SD1){ref-type="supplementary-material"}). Surprisingly, nascent RNA transcription on enhancers correlated with BRD4 occupancy to a greater extent than the other investigated profiles ([Figures 4E](#F4){ref-type="fig"}--[4H](#F4){ref-type="fig"}). RNAPII occupancy is also well associated with BRD4 on enhancers ([Figure 4E](#F4){ref-type="fig"}). Interestingly, high eRNA-producing EREs exhibited high E2-induced RNAPII recruitment that extended to more than 5 kb upstream and downstream of the ERE summits, suggesting a tight association between RNAPII recruitment and elongation at eRNA-producing enhancers ([Figures 4I](#F4){ref-type="fig"} and [S4N](#SD1){ref-type="supplementary-material"}). ChIP analyses confirmed that E2-induced RNAPII recruitment and elongation at the GREB1 ERE are decreased by JQ1 treatment ([Figures 4J](#F4){ref-type="fig"}, [4K](#F4){ref-type="fig"}, and [S4O](#SD1){ref-type="supplementary-material"}). Altogether, these studies suggest that in addition to its role in transcriptional elongation, BRD4 affects both recruitment and elongation of RNAPII on ERα-dependent enhancers.

Importantly, BRD4 depletion or inhibition significantly decreased eRNA synthesis from E2-regulated enhancers ([Figure 4L](#F4){ref-type="fig"}). This suggests that in addition to its reported *cis*-regulatory function, BRD4 may stimulate E2-induced mRNA transcription by promoting eRNA production at distal EREs.

DISCUSSION {#S9}
==========

The hierarchical epigenetic regulation of transcriptional activation involves an intricate network of interactions among various transcription factors, histone-modifying enzymes, epigenetic readers, and the transcriptional machinery. In this study, we investigated the function of the epigenetic reader BRD4 in controlling E2-regulated gene transcription. Our findings support a model in which ERα recruits histone acetyltransferases to a subset of EREs enriched for FOXA1 to facilitate histone acetylation and subsequent recruitment of BRD4 and RNAPII in order to promote eRNA synthesis ([Figure 4M](#F4){ref-type="fig"}).

To date, most studies have focused largely on the role of BRD4 as a promoter proximal regulator of mRNA synthesis by increasing P-TEFb recruitment. Consistent with a direct function of BRD4 on target gene transcription, we show that BRD4 promotes elongation-associated phosphorylation of RNAPII and monoubiquitination of histone H2B. These results are consistent with an established essential role for H2Bub1 in E2-stimulated transcription ([@R41]) and the dependence of H2Bub1 upon CDK9 ([@R40]). In addition to a *cis-*regulatory function of BRD4, our results uncover a role for BRD4 on enhancers. This is consistent with a previous finding that CDK9 is recruited by BRD4 to distal intergenic enhancer regions marked by H3K27ac ([@R32]). Notably, we show that BRD4 co-occupies eRNA-producing enhancers with ERα, FOXA1, and H3K27ac, regulates RNAPII recruitment on ERα-bound enhancers, and is required for the production of eRNA transcripts. These findings support a role for BRD4 in hormone-dependent cancers ([@R4]) and suggest a model in which eRNA synthesis requires a coordinated epigenetic hierarchy that culminates in the recruitment of BRD4 and RNAPII and subsequent transcription from a select subset of distal EREs.

The importance of BRD4 in E2-regulated transcription is consistent with previously identified interactions between BRD4 and ERα ([@R55]) as well as ERα and CDK9 ([@R44]) or cyclin T1 ([@R54]). Furthermore, the 7SK component HEXIM1, which suppresses P-TEFb activity, negatively regulates ERα transcriptional activity ([@R54]), and its overexpression induces tamoxifen resistance ([@R23]). Importantly, recent data showed that CDK9 activity is required for the production of eRNAs at distal EREs ([@R16]) and the role of eRNA and MED1 in regulating AR-dependent transcription and looping ([@R18]). Thus, consistent with our model, P-TEFb and BRD4 likely promote ERα-mediated transcriptional activation at least in part by promoting eRNA transcription.

ERα functions together with Cohesin to nucleate chromosomal looping that promotes E2-regulated transcription ([@R15]; [@R43]). Our previous study showed that proteasomal inhibition specifically decreases ERα-regulated transcription by decreasing H2Bub1 and transcriptional elongation without affecting long-range chromosomal interactions ([@R41]). Consistently, CDK9 inhibition decreased ERα-dependent gene expression without affecting ERα occupancy, coactivator recruitment, or chromosomal looping ([@R16]). Similarly, our data show that BRD4 inhibition had little or no effect on ERα recruitment, E2-stimulated H3K27 acetylation, or Cohesin recruitment, indicating that BRD4 functions along with CDK9 downstream of early enhancer activation events but precedes RNAPII recruitment and elongation.

Numerous recent studies have shown a substantial therapeutic potential for BRD4 inhibition in various malignant diseases ([@R4]; [@R13]; [@R17]; [@R31]; [@R36]; [@R58]; [@R61]), leading to the testing of several BET domain inhibitors in a clinical setting for certain types of tumors ([@R12]). However, the utility of BET inhibitors in ERα^+^ breast cancer has not been investigated. Here, we describe a function of BRD4 in specifically controlling E2-dependent gene transcription in ERα^+^ normal and malignant cells in vitro and in vivo. We provide mechanistic insight to support a previously unknown mechanism by which BRD4 controls distal enhancer activity and target gene expression by promoting eRNA synthesis. We hypothesize that this BRD4-dependent mechanism likely controls other enhancer-driven transcriptional programs directing processes such as lineage specification during cell differentiation and development. Moreover, these findings may potentially serve to provide a mechanistic-based approach to the treatment of ERα^+^ breast cancer.

EXPERIMENTAL PROCEDURES {#S10}
=======================

Cell Culture, Transfections, Inhibitors, and siRNAs {#S11}
---------------------------------------------------

MCF7 cells were provided by K. Pantel (University Medical Center, Hamburg-Eppendorf), Ishikawa from T. Spelsberg (Mayo Clinic, Rochester), and H1299 from M. Dobbelstein (University Medical Center, Göttingen). They were grown in phenol red-free high-glucose Dulbecco's modified Eagle's media (DMEMs; Invitrogen) supplemented with 10% bovine growth serum (Thermo Scientific), 1% sodium pyruvate, and 1% penicillin/streptomycin (Sigma-Aldrich). Forward and reverse transfections were performed using DharmaFECT 1 (Thermo Scientific) for small interfering RNAs (siRNAs) according to the manufacturer's instructions. Nontargeting (negative control) and BRD4 siRNAs (siBRD4s) were obtained from Dharmacon (Thermo Scientific). BRD4 SmartPool siRNA (Dharmacon) contained the sequences 5**′**-AGCUGAACCUCCCUGAUUA-3**′**, 5**′**-UGAGAAAUCUGCCAGUAAU-3**′**, 5**′**-UAAAUGAGCUACCCACAGA-3**′**, and 5**′**-GAACCUCCCUGAUUACUAU-3**′**. JQ1 (150 nM) was used to pretreat the cells 30 min before E2 induction. 17 β-estradiol and ethinyl estradiol (Sigma-Aldrich) were used at the concentration of 10 nM. DMSO or ethanol was used as Veh. ICI182780 (Fulvestrant) was used at the concentration of 1 μM. TGF-β1 (2 ng/ml) treatment was done on H1299 cells for 90 min.

E2-induction experiments were carried out by changing the media to DMEM supplemented with 5% charcoal-dextran-treated fetal bovine serum (CSS; Sigma-Aldrich), 1% sodium pyruvate, and 1% penicillin/streptomycin after 24 hr of cell growth. After 48 hr of hormone deprivation, they were treated with 17 β-estradiol for 2, 6, or 24 hr. Ethinyl estradiol was used for proliferation assays in Ishikawa cells. TGF-β1 treatment in H1299 cells was given after growing the cells in serum-free media for 48 hr.

MCF-7 cells were harvested for RNA upon Veh or E2 treatment, and negative control siRNA (siCont), siBRD4, or JQ1 transfection. JQ1-treated cells were also transfected with negative siCont. Ishikawa and H1299 cells were harvested for RNA under Veh or E2 treatment, or TGF-β1 treatment and negative siCont or siBRD4.

RNA-Seq {#S12}
-------

RNA integrity was checked using Bioanalyzer 2100 (Agilent Technologies). A total of 500 ng of total RNA was used for preparing libraries using TruSeq RNA Sample Preparation Kit (Illumina), and the size range was checked to be 280 bp using Bioanalyzer. These samples were amplified and sequenced by using cBot and HiSeq 2000 from Illumina, respectively, for 51 bp single-ended tags with single indexing. Images from the sequencing results were processed using BaseCaller to bcl files function in Illumina software. These were demultiplexed to fastq files using CASAVA 1.8.2 and mapped to the human reference transcriptome (UCSC HG19) using Bowtie 2 (version 2.1.0) ([@R26]). Read counts for each sample and each gene were aggregated using a custom Ruby script. DESeq (version 1.14.0) was used for measuring differential expression ([@R3]).

Gene Set Enrichment Analysis {#S13}
----------------------------

Pathway enrichment scores were calculated by GSEA ([@R46]). The gene expression data from RNA sequencing (RNA-seq) analyses are sorted by correlation with log2-fold changes between different conditions. This sorted expression data set was compared with C2-curated gene sets that include published gene sets from pathways of chemical and genetic perturbations, canonical pathways, BIOCARTA, Reactome, and KEGG. WILLIAMS_ESR1_TARGETS_UP ([@R53]), FRASOR_RESPONSE_TO_ESTRADIOL_UP ([@R14]), MASSERWEH_RESPONSE_TO_ESTRADIOL ([@R33]), BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP ([@R6]), DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP ([@R11]), PID_HNF3A_PATHWAY ([@R42]), STEIN_ESR1_TARGETS ([@R45]), MASSERWEH_TAMOXIFEN_RESISTANCE_DN ([@R33]), and CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4 ([@R9]) are shown as E2-related topmost enriched pathways under BRD4 perturbation.

ChIP {#S14}
----

ChIP and subsequent real-time PCR analyses with specific primers ([Table S3](#SD1){ref-type="supplementary-material"}) were performed as before ([@R41]; [@R5]) for BRD4, ERα, RAD21, H3K27ac, and H2Bub1. ChIP-seq was performed for BRD4, ERα, and H2Bub1. BRD4 ChIP was performed by crosslinking the chromatin for 20 min in 1% formaldehyde. Other antibodies and their dilutions were used as described before ([Table S1](#SD1){ref-type="supplementary-material"}) ([@R41]; [@R5]).

ChIP-Seq and Bioinformatic Analyses {#S15}
-----------------------------------

Prior to library preparation, immunoprecipitated DNA was sonicated an additional time to ensure fragment sizes less than 200 bp. Libraries were prepared using the NEBNext Ultra DNA library preparation kit according to the manufacturer's instructions. Size range was verified to be 280--300 bp using Bioanalyzer 2100. A total of 50 cycles were used for amplification in cBot, and 101 bp single-ended tags for BRD4 and 51 bp single-ended tags for other ChIP samples were sequenced with single indexing using Illumina HiSeq 2500. Raw data for FOXA1, H3K4me3, H3K27me3 ([@R20]), H3K27ac ([@R48]), RNAPII ([@R52]), DNase sequencing (DNase-seq) ([@R50]), and global run-on (GRO) sequencing (GRO-seq) ([@R16]) were downloaded from the European Nucleotide Archive, and their accession numbers are listed in [Table S4](#SD1){ref-type="supplementary-material"}. The reads were mapped to the human reference genome (UCSC HG19) using Bowtie (version 1.0.0) ([@R27]). Peak calling was done by Model-based Analysis of ChIP-Seq (version 1.4.2) ([@R56]). Coverage was determined by normalizing the total number of mapped reads per hundred million. For plotting correlation, aggregation, ChIP enrichment signals over specific genomic features, and heatmaps, Cistrome ([@R29]) based on the Galaxy framework was used. Data were visualized in Integrative Genomics Viewer (version 2.3.14) ([@R49]). Common TSS and gene body coordinates were obtained from UCSC Table Browser ([@R21]). Distal EREs were defined as ERα binding sites not within gene bodies or regions 5 kb upstream or downstream thereof. Regions covering the TSS and 3 kb downstream of it were used for TSS-oriented correlation plots and 1.5 kb up- and downstream to distal EREs for distal ERE-oriented correlation plots. Average signals of GRO-seq data with E2 treatment were calculated using assign weighted average function in Cistrome surrounding TSS (plus 3 kb) or ERE (±1.5 kb). These values were used to group the TSS or ERE coordinates as high, medium, low, and null. For distal EREs, the "high" group corresponds to distal EREs having a weighted average greater than 0.45, "medium" has \>0.25 \<0.45, "low" has \>0 ≤.25, and "null" has a zero (0) average. For TSSs, the "high" group corresponds to distal EREs having a weighted average greater than 0.3, "medium" has ≥.15 \<0.3, "low" has \>0 \<0.15, "null" has a zero (0) average. The range for these groups was chosen according to the similar number of TSSs or EREs in each group and adequate GRO-seq enrichment signal defined for each group. H3K27me3-positive coordinates were obtained using the summits of H3K27me3 ChIP-seq signal ([@R20]). For measuring statistical significance of aggregate plots, weighted averages for each E2-up-regulated gene, 1.5--2.5 kb downstream of each TSS or distal ERE ±100 bp, were used to compute a multiple-linear regression model. Within the multiple-linear regression model, the weighted average within a 1 kb window was used as a dependent variable, given the independent variables of condition and gene. The condition variable was tested for significant impact using an ANOVA. Groups of E2-upregulated genes based on RNAPII occupancy (RNAPII recruited de novo, RNAPII preloaded and recruited, and RNAPII constitutively bound) were kindly provided by W. Lee Kraus. E2 up- (≥ 1.5-fold), down- (≤0.8-fold), and nonregulated genes were retrieved from RNA-seq data.

In Vivo Experiments in JQ1-Injected Mice {#S16}
----------------------------------------

Three-week-old C57BL/6 female mice were injected intraperitoneally with JQ1 (50 mg/kg) or Veh (5% DMSO in 5% dextrose) for 3 weeks (n = 8 for each group). Mice were sacrificed via CO~2~ inhalation, and uteri were collected to examine differences in their size and weight. Difference in the uterine weight between control (DMSO) and JQ1-injected mice was calculated by normalizing the uterine wet weight (in milligrams) with respect to body weight (in grams). Uteri (n = 4 for each group) were homogenized using beads by FastPrep FP120 homogenizer (Thermo Scientific), and RNA was isolated using TRIzol (QIAGEN) according to manufacturer's instructions. Normalization was done using starting quantity values of glyceraldehyde 3-phosphate dehydrogenase. Relative mRNA expression analyses were done as mentioned before (but not normalized for control conditions) using gene-specific primers for the E2-dependent and cell-cycle-related genes *Ran* and *Mad2l1* ([@R47]) and the reproduction-related gene *Il1b* ([@R51]). Primers are listed in [Table S2](#SD1){ref-type="supplementary-material"}. Statistical significance was analyzed using Student's t test. All animal studies were performed in compliance with the requirements of the German Animal Welfare Act.
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![BRD4 Perturbation Impairs E2-Induced Gene Expression, RNA Polymerase Ser2 Phosphorylation, and H2Bub1\
(A) Heatmap made with log2-fold changes from mRNA-seq of MCF7 cells. E2 denotes siCont and E2-treated samples relative to cells transfected with siCont and Veh treated. siBRD4+E2 denotes siBRD4 and E2-treated samples relative to siCont with E2 induction. JQ1+E2 denotes siCont, JQ1, and E2-treated samples relative to siCont with E2 induction. Only E2-upregulated genes ≥ 1.5-fold are shown. Adjusted p value is ≤ 0.05.\
(B) GSEA of mRNA expression data from RNA-seq. The table shows the enrichment score for the topmost estrogen-related pathways in each condition. Nominal p value is ≤0.05, FDR ≤25%.\
(C and D) Western blot analyses with specific antibodies on whole MCF7 protein extracts after transfection with negative control (−) or siBRD4 with 6 or 24 hr of E2 induction (C) or DMSO (−) or JQ1 and/or E2 induction for 24 hr (D). Relative quantified values of H2Bub1 normalized with H2B and ERα with HSC70 are indicated under the respective blots.\
See also [Figures S1A--S1J](#SD1){ref-type="supplementary-material"}.](nihms756893f1){#F1}

![Inhibition and Knockdown of BRD4 Affect Proliferation and Uterine Growth\
(A) Cell proliferation assays in MCF7 cells upon E2 as well as basal conditions under negative siCont, siBRD4, JQ1, and ICI182780 treatment.\
(B--D) Three-week-old mice injected with Veh (Cont \[control\]) and JQ1 for 3 weeks were dissected, and uteri were analyzed for their size (B) and wet weight (wt.) (C). \*\*\*p ≤ 0.001. Data are represented as mean ± SD (n = 8). (D) Single-gene expression analyses of E2-induced genes (*Ran*, *Mad2l1*, and *Il1b*) after Veh (cont) or JQ1-injected mouse uteri. \*p ≤ 0.05; \*\*p ≤ 0.01. The data are represented as median ± SD (n = 4). Rel. mRNA exp., relative mRNA expression.\
See also [Figures S2A--S2C](#SD1){ref-type="supplementary-material"}.](nihms756893f2){#F2}

![BRD4 Occupies Promoters and Correlates with Active Transcription\
(A) Genomic binding profiles of BRD4 on E2-induced genes (*GREB1* and *TFF1*) and a housekeeping gene (*ACTB*). Red indicates E2-treated and green indicates Veh-treated conditions.\
(B) Aggregate plots showing genomic binding profiles of BRD4 on E2-upregulated gene-specific TSS upon Veh and E2-treated conditions. x axis shows the distance from the TSS of E2-upregulated genes in kilobase pairs. y axis shows the average BRD4 signal of the reads normalized per hundred million base pairs. TSS is marked with a black dotted line.\
(C) Aggregate plots showing genomic profiles of H2Bub1 on E2-upregulated genes upon Veh, JQ1, as well as Veh (JQ1 Veh), E2, and JQ1 as well as E2 (JQ1 E2)-treated conditions. Weighted averages for each E2-upregulated gene, 1.5--2.5 kb downstream of each TSS, were used to calculate the p values using ANOVA with multiple-regression model. \*\*\*p ≤ 0.001.\
(D) Genomic profiles of H2Bub1 on *GREB1*, *TFF1*, and *ACTB*. Red indicates E2-treated and green indicates JQ1 as well as E2 (JQ1 E2)-treated conditions.\
(E) Correlation plot on E2-regulated gene-specific TSS +3 kb showing the association of BRD4, H3K27ac, H3K4me3, nascent RNA transcription (GRO-seq), RNAPII, H2Bub1, and DNase I-hypersensitivity sites (DNase-seq) and H3K27me3.\
(F) Aggregate plot analyses of BRD4, H3K27ac, RNAPII, and H2Bub1 on GRO-seq-based groups (high, medium, low, and null), at specific TSSs on E2-regulated genes. "High" group corresponds to E2-upregulated TSS having a weighted average of GRO-seq signal from E2-treated MCF7 cells \>0.3, "medium" ≥0.15 \<0.3, "low" \>0 \<0.15, and "null" with no value of average. A class of H3K27me3-positive summits was examined as a negative control of active transcription.\
See also [Figures S3A--S3R](#SD1){ref-type="supplementary-material"}.](nihms756893f3){#F3}

![BRD4 Binds to ER^+^ Enhancers after ERα Recruitment and H3K27ac and Regulates eRNA Synthesis\
(A) ChIP-quantitative PCR (ChIP-qPCR) analyses of ERα occupancy on *GREB1* ERE after DMSO or JQ1 treatment with Veh or E2 induction. \*\*\*p ≤ 0.001. Data are represented as mean ± SD (n = 3). Dotted line indicates background.\
(B) Aggregate plot showing genomic binding profiles of ERα on distal EREs upon E2-treated and JQ1 as well as E2 (JQ1 E2)-treated conditions. x axis shows the distance from the center of ERE in kilobase pairs. y axis shows the average ERα signal of the reads normalized per hundred million base pairs. Weighted averages for each ERE ±100 bp were used to calculate the p values using ANOVA with repeated measures with ANOVA with multiple-regression model. p value is mentioned in the plot.\
(C) ChIP-qPCR analyses of H3K27ac after DMSO or JQ1 treatment with Veh or E2 induction on *GREB1* ERE overlapping region and *GREB1* TSS. The data are represented as mean ± SD (n = 3). \*\*p ≤ 0.01; n.s., not significant.\
(D) Aggregate plot showing genomic binding profiles of BRD4 on distal EREs upon Veh and E2-treated conditions.\
(E) Correlation plot on distal EREs ±1.5 kb showing the association of BRD4, H3K27ac, ERα, FOXA1, nascent RNA transcription (GRO-seq), RNAPII, DNase-seq, and H3K27me3.\
(F) Aggregate plot analyses of BRD4, H3K27ac, ERα, FOXA1, and RNAPII occupancy on GRO-seq-based classified distal EREs. "High" group corresponds to distal EREs having a weighted average \>0.45, "medium" \>0.25 \<0.45, "low" \>0 ≤ 0.25, and "null" with no value of average.\
(G) Heatmap profiles of BRD4, H3K27ac, ERα, FOXA1, nascent RNA transcription (GRO-seq), and RNAPII occupancy on ±5 kb of distal EREs aligned from high to null GRO-seq signals. Center of each heatmap denotes center of distal EREs.\
(H) Binding profiles of BRD4, H3K27ac, ERα, GRO-seq, and RNAPII on *GREB1* proximal and distal EREs and promoter. BRD4 with red peaks indicates E2-treated and green indicates Veh-treated conditions. RNAPII with blue peaks indicates E2-treated and light green indicates Veh-treated conditions.\
(I) Aggregate plot showing genomic binding profiles of RNAPII on distal EREs that produce high eRNA (GRO-seq group "high") upon Veh and E2-treated conditions. (J and K) ChIP-qPCR analyses of RNAPII\
(J) and RNAPII-PSer2 (K) occupancy on *GREB1* ERE after DMSO or JQ1 treatment with Veh or E2 induction. \*p ≤ 0.05. Data are represented as mean ± SD (n = 3). Dotted line indicates background.\
(L) eRNA-qPCR results showing E2-induced eRNA (e*GREB1* and e*XBP1*) upon negative siCont, siBRD4, or JQ1 treatment with Veh or E2 induction. Relative RNA levels are shown as "Rel. RNA levels." Data are represented as mean ± SD (n = 3).\
(M) Model depicting the role of BRD4 on E2-induced transcription. ER, ERα; HAT, histone acetyltransferase; ac, histone acetylation; S2P, RNAPII p-Ser2; Ub, H2Bub1.\
See also [Figures S4A--S4N](#SD1){ref-type="supplementary-material"}.](nihms756893f4){#F4}
